Rizatriptan for the acute treatment of migraine: Consistency, preference, satisfaction, and quality of life

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 251-258

  Amoozegar, Farnaz ^a   Pringsheim, Tamara ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Migraine; Patient preference; Rizatriptan

Indexed keywords

EID: 84867260178     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S6152     Document Type: Review

References (27)

1. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans in acute migraine treatment: a meta-analysis of 53 trials. Cephalalgia. 2002; 22:633-658.
2. Dowson JA, Tepper SJ, Dahlof C. Patients' preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain. 2005;6:112-120.
3. Dahlof CGH, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD. Within-patient consistency of response of rizatriptan for treating migraine. Neurology. 2000;55:1511-1516.
4. Block GA, Goldstein J, Polis A, Reines SA, Smith ME; the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998;38:764-771.
5. Göbel H, Heinze A, Heinze-Kuhn K, Lindner V. Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. Headache. 2001;41:264-270.
6. Láinez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia. 2006;26:246-256.
7. Loder E, Brandes JL, Silberstein S, et al; Rizatriptan Protocol 060 Study Group. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache. 2001;41:745-753.
8. Pascual J, Bussone G, Hernandez JF, Allen C, Vrijens F, Patel K; Rizatriptan-Sumatriptan Preference Study Group. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. Eur Neurol. 2001;45:275-283.
9. Díez FI, Straube A, Zanchin G. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol. 2007; 254:242-249.
10. Ng-Mak DS, Hu XH, Chen Y, Ma L, Solomon G. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. Int J Clin Pract, 2007;61:1091-1111.
11. Adelman JU, Mannix LK, Von Seggern RL. Rizatriptan tablet versus wafer: patient preference. Headache. 2000;40:371-372.
12. Christie S, Göbel H, Mateos V, Allen C, Vrijens F, Shivaprakash M; Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol. 2003;49:20-29.
13. Pascual J, García-Moncó C, Roig C, Yusta Izquierdo A, López-Gil A; eMAX Study Group. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: Analysis of Return to Function and Patient Preference. Headache. 2005;45:1140-1150.
14. Bell CF, Foley KA, Barlas S, Solomon G, Hu XH. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usualcare oral medications in the acute treatment of migraine headaches: A multicenter, prospective, open-label, two-attack, crossover study. Clin Ther. 2006;28:872-880.
15. Láinez MJA, Lopez A, Pacual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache. 2005;45:883-890.
16. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache. 1998;38:737-747.
17. Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine. Eur Neurol. 1999;42:173-179.
18. Freitag F, Taylor F, Hamid M, et al. Elimination of migraine associated nausea in patients treated with rizatriptan orally disintegrating tablet: a randomized double blind placebo controlled study. Headache. 2008;48:368-377.
19. Kramer M, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology. 1998;51:773-781.
20. Pascual J, Vega P, Diener H, Allen C, Vrijens F, Patel K. Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia. 2000;20:455-461.
21. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache. 1998;38:748-755.
22. Santanello N, Polis A, Hartmaier S, Kramer M, Block G, Silberstein S. Improvement in migraine specific quality of life in a clinical trial of rizatriptan. Cephalalgia. 1997;17:867-872.
23. Teall J, Tuchman M, Cutler N. Rizatriptan for the acute treatment of migraine and migraine recurrence. A placebo controlled, outpatient study. Headache. 1998;38:281-287.
24. Ahrens S, Farmer M, Williams D, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19:525-530.
25. Gerth W, Ruggles K, Stark S, Davies G, Santanello N. Improvement in health related quality of life with rizatriptan 10 mg compared with standard migraine therapy. Clin Drug Invest. 2001;21:853-860.
26. Cutler N, Mushet G, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995;45(8 Suppl 7):S5-S9.
27. Mathew N, Asqharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology. 1997;49:1485-1490.